KDR and cancer: These mAbs mainly target CD20 [20–22], antitumor necrosis factor (TNF) α [23, 24], VEGFR [25–27], HER 2 [28, 29], and EGFR [30, 31] for the treatment of cancer or immunological disorders [32].